Milestone Pharmaceuticals Secures $125M to Accelerate Etripamil's Journey in Cardiovascular Care

Milestone Pharmaceuticals Inc.

(Nasdaq: MIST) is excited to announce a significant funding milestone with the successful raise of $125,000,000, a testament to our steadfast commitment to transforming cardiovascular care.

This substantial investment will accelerate the development and commercialization of etripamil, our novel, potent, and short-acting calcium channel blocker, which is currently being developed as a rapid-onset nasal spray for the termination of paroxysmal supraventricular tachycardia (PSVT).

As a Phase 3 clinical-stage biopharmaceutical company, Milestone Pharmaceuticals is at the forefront of innovative treatments, and this funding will enable us to advance our Phase 3 clinical trial for etripamil in PSVT while expanding our clinical research pipeline.

The new capital is earmarked not only for the ongoing Phase 3 trial but also for initiating a Phase 2 study in atrial fibrillation, another critical rapid heart rate condition, as well as an additional Phase 2 trial in angina.

These studies are expected to pave the way in establishing proof-of-concept for the broader application of etripamil, further solidifying our position as a leader in cardiovascular therapeutics.

We also want to remind our community to remain vigilant about recruitment scams that misuse our name; please refer to our official Careers page for verified job openings.

This funding round marks a pivotal moment in our journey and underscores our dedication to developing breakthrough therapies that offer rapid intervention and improved quality of life for patients managing potentially life-threatening cardiovascular episodes.

We look forward to the continued support from our investors, partners, and the medical community as we work tirelessly towards delivering life-changing solutions.